Intellisness Scientific Committee

The Intellisness Scientific Committee is comprised of independent representatives from the academic research environment, the pharmaceutical industry and the financial sector. This committee provides a strategic overview combined with insider knowledge on scientific and technological advances, as well as major trends in the market. It advises which themes should be given priority to. The members of this experienced team represents the core values held by Intellisness.

Franck Atienzar, Associate Director, Non-clinical Development, UCB Biopharma, Belgium

After obtaining a doctorate in Environmental Toxicology at the University of Plymouth (England, 2000), Franck began his career with Sigma-Aldrich. He currently works with the UCB Biopharma laboratory (Braine-l’Alleud, Belgium), which he joined as head of the in vitro toxicology department unit in 2002. He is now Associate Director. As a specialist in cellular and molecular biology and toxicology, he has been acting as scientific expert for the European Commission since 2004, while continuing his role at UCB Biopharma. Franck is the author of 29 scientific publications, co-author of 4  book chapters, and lectures. He also contributes to the training of scientists (lectures), working with Pharmed (a post-graduate programme in pharmaceutical medicine, ULB (private research university), Belgium) and the Paul Verlaine University (Metz, France).

Luca Bolliger, VP and Director Corporate Licensing, Recordati

Luca studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He graduated at the Biocenter in Basel in biochemistry, and then became Member of the Basel institute for immunology. He then joined the pharmaceutical industry as a Global discovery portfolio manager in the Pharma Strategy Unit at Hoffmann-La

Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management, and as a freelance consultant. He established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at Actelion. Luca Bolliger joined

Recordati from Novimmune where he was director Business Development

Daniel Christiaen, CNRS (French National Centre for Scientific Research) – Director of Economic Development, Observatoire Océanologique de Banyuls (marine station), France

Director of Research, in charge of partnerships and development for the CNRS and the Etablissement Français duSang (French blood authority), Assistant Director of the GREPI laboratory (research laboratory for inflammatory processes). Not only does Daniel have exceptional knowledge in the living sciences, he has also created several companies: Pronatec, Kalys, Genoscreen, Animascope. Treasurer of the Compétence Biotech association, he is also co-author of the book entitled “Au pays des chercheurs” (In the land of researchers). Daniel has won many prizes throughout his career, including the “Coup de Cœur de l’économie sociale et solidaire” (social and collectively responsible economy) awarded by the Rhône Alpes regional council in 2009 and “Innotrophés – Prix de l’Innovation Managériale” (managerial innovation) awarded by the Grenoble Chamber of Commerce and Industry in 2010.

Anita Marguerie de Rotrou, Translational Research Programme Manager, University of Cambridge, UK.

After graduating with a doctorate in Developmental Biology from the University of London, followed by a post-doctorate at Cancer Research UK in 2002, Anita has pursued a career in biotechnology companies, specialising in stem cells as well as scientific and technological partnerships. Since 2015 she has been in charge of the advancement of translational projects for emerging science for the University of Cambridge for products, medical devices and first in man clinical trials, working closely with the technology transfer department; as well as working on partnerships between pharmaceuticals, biotechnology and academia for human health. Cambridge is the most important centre for biotechnology and human health in Europe.


Jacques Bernard Taste, founder and President of Biotech Finances

After graduating from the University of Lyon, Jacques-Bernard worked for his entire career in the financial press sector. In 1996 he created CAD, an independent press agency, delivering news feeds and finished articles to the major financial and professional media titles in Europe and Asia. In 1999 he was invited by the Echos media group to actively participate in the launch of their professional newsletter department, in particular the IAD and Biotechnologies and Finances newsletters. In 2004 he bought the Biotechnologies & Finances newsletter from the Echos group, and has since turned it into one of the leaders in financial information for the biotechnology and medical technology sectors. Biotech Finances now has offices in France, Canada and Belgium. They recently established a prestigious French-speaking and international editorial committee comprising investors, industrialists, academics and literary figures. Jacques-Bernard has now been a well-placed and attentive observer of the biotechnology and medical technology sectors for nearly twenty years. An astute connoisseur, he is capable of deciphering trends and understands the financial stakes.

Tel +33(0)9 72 57 61 44

Le  Concorde,

24 rue Lamartine

38320 Eybens